An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.
Journal of eating disorders January 3, 2026 Jesse Dallery, Jennifer L Miller, Jeff Boissoneault et al. 1 citation
In a small open-label pilot study, five adults with binge-eating disorder received a single 25 mg dose of psilocybin combined with Acceptance and Commitment Therapy. No serious adverse events occurred. All participants reported fewer binge-eating episodes through the 14-week follow-up, along with improvements in depression, anxiety, and psychological flexibility. Three participants also lost weight and reduced waist circumference. Because the study was unblinded and had only five participants, the results cannot confirm cause and effect. Brain scans showed hints of increased activity in regions linked to cognitive control and self-awareness when viewing processed versus unprocessed food images. These findings point toward larger, controlled trials.